ArticleAJNR. American journal of neuroradiology2026
Patient-Reported Symptom Relief from Percutaneous Benign Thyroid Nodule Radiofrequency Ablation in Routine Clinical Care.
Article in AJNR. American journal of neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
background and purposeWe investigated patient-reported symptom relief from percutaneous ultrasound-guided radiofrequency ablation (RFA) of benign thyroid nodules in routine clinical care, given that prior studies have reported efficacy based on size reduction and specific symptom scores but not patient-reported effectiveness. MATERIALS AND
methodsThis retrospective cohort study included all consecutive adults treated between May 12, 2021 and August 7, 2024 with ultrasound-guided RFA for symptomatic benign thyroid nodules at a quaternary care hospital. Procedures were performed by a single board-certified neuroradiologist utilizing a trans-isthmus moving shot technique. Patient-reported symptom relief (symptoms resolved yes/no) was assessed at 6-month routine clinical follow-up. Descriptive statistics were performed. Preablation nodule size associations with symptom resolution were assessed with Wilcoxon tests.
resultsForty-nine patients (mean age, 56.6 ± 13.1 years; 45 women) had average preablation nodule volume of 30.6 ± 31.0 mL, higher than the 20.1 ± 22.4 mL reported in a recent meta-analysis of efficacy studies. Common preablation symptoms were cosmetic deformity (37/49, 77.1%), dysphagia (28/49, 58.3%), and dysphonia (15/49, 30.6%). Thirty-six patients (73.0%) completed at least 1 follow-up visit. Postablation symptom resolution was 78.0% (28/36, 95% CI, 61.9%-88.3%) among those with follow-up, higher than the 64.4% reported in the single study included in the meta-analysis that assessed subjective symptom relief. Relative mean volume reduction was 52.3% ± 27% in those with follow-up and was associated with symptom resolution (59% reduction with symptom resolution versus 30% without;
conclusionsPatient-reported symptom relief from percutaneous ultrasound-guided thermal ablation of benign thyroid nodules in our clinic has resulted in approximately 80% clinically relevant effectiveness based on patient-reported symptom relief, with a slightly lower volume reduction rate compared with those reported in efficacy studies. Our clinic patients had larger nodule volumes than typical in published studies and many patients opted to forgo posttreatment follow-up. This likely led to underestimation of our effectiveness and volume reduction measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.